Saavedra HD

Idioma: Español
Referencias bibliográficas: 42
Paginas:
Archivo PDF: 191.75 Kb.

RESUMEN

La molécula CD28 es considerada uno de los receptores coestimuladores más importantes en las células T, necesaria para la completa activación celular. En los últimos años se ha acumulado suficiente evidencia sobre su participación en los mecanismos conocidos como señal 2 de activación celular o coestimuladora. De esta forma se convierte en un blanco atractivo para estrategias terapéuticas en enfermedades autoinmunes y trasplante de órganos. Esta revisión se concentra en los principales mecanismos por los cuales esta molécula participa en la completa activación de las células T.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Acuto O, Mise-Omata S, Mangino G, Michel F. Molecular modifiers of T cell antigen receptor triggering threshold: the mechanism of CD28 costimulatory receptor. Immunol Rev 2003;192:21–31.

2. Rudd CE, Taylor A, Schneider H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev 2009; 229:12–26.

3. Leitnera J, Grabmeier-Pfistershammerb K, Steinbergera. Receptors and ligands implicated in human T cell costimulatory processes. Immunology Letters 2010; 128: 89–97.

4. Bluestone J. New perspectives of CD28-B7 mediated T cell costimulation. Immunity 1995;2:555–9.

5. Linsley PS. Distinct roles for CD28 and cytotoxic T lymphocyte-associated molecule 4 receptor during T-cell activation. J Exp Med 1995;182:289–92.

6. Rudd CE. The reverse stop-signal model for CTLA4 function. Nat Rev Immunol 2008;8:153–60.

7. Podojil JR, Miller SD. Molecular mechanisms of T-cell receptor and costimulatory molecule ligation/blockade in autoimmune disease therapy. Immunol Rev 2009;229:337–55.

8. Li XC, Rothstein DM, Sayegh MH. Costimulatory pathways in transplantation: challenges and new developments. Immunol Rev 2009;229:271–93.

9. Garçon F, Patton DT, Emery JL, Hirsch E, Rottapel R, Sasaki T, et al. CD28 provides T-cell costimulation and enhances PI3K activity at the immune synapse independently of its capacity to interact with the p85 ⁄ p110 heterodimer. Blood 2008;111:1464–71.

10. van der Merwe P, Bodian D, Daenke S, Linsley PS, Davis SJ. CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics. J Exp Med 1997;185:393–403.

11. Chattopadhyay K, Lazar-Molnar E, Yan Q, Rubinstein R, Zhan C, Vigdorovich V, et al. Sequence, structure, function, immunity: structural genomics of costimulation. Immunol Rev 2009;229:356–86.

12. Schneider H, Smith X, Liu H, Bismuth G, Rudd C. CTLA-4 expression disrupts ZAP-70 microcluster formation, T-cell ⁄ APC conjugation and calcium mobilization. Eur J Immunol 2007;38:40–7.

13. Gary A. Koretzky GA. T Lymphocyte Signaling Mechanisms and Activation. En: Paul W.E. Fundamental Immunology. 6th edition. Washington, DC: Lippincott Williams & Wilkins; 2008.347-72.

14. Driessens G, Kline J, Gajewski TF. Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol Rev 2009;229:126–44.

15. Kölsch U, Arndt B, Reinhold D, Lindquist JA, Jüling N, Kliche S, et al. Normal T-cell development and immune functions in TRIM-deficient mice. Mol Cell Biol 2006;26:3639–48.

16. Wang H, Rudd CE. SKAP-55, SKAP-55- related and ADAP adaptors modulate integrin-mediated immune-cell adhesion.Trends Cell Biol 2008;18:486–93.

17. Harada Y, Ohgai D, Watanabe R, Okano K, Koiwai O, Tanabe K, et al. A single amino acid alteration in cytoplasmic domain determines IL-2 promoter activation by ligation of CD28 but not inducible costimulator (ICOS). J Exp Med 2003;197:257–62.

18. Tavano R, Gri G, Molon B, Marinari B, Rudd CE, Tuosto L, et al. CD28 and lipid rafts coordinate recruitment of Lck to the immunological synapse of human T lymphocytes. J Immunol 2004;173:5392–7.

19. Holdford AD, Green JM, Levin SD, Denny MF, Straus DB, Link PS, et al. Proline residues in CD28 and the Src homology (SH)3 domain of Lck are required for T cell costimulation. J Exp Med 1999;190:375–84.

20. Sanchez-Valdepenas C, Martin AG, Ramakrishnan P, Wallach D, Fresno M. NFkappaB-inducing kinase is involved in the activation of the CD28 responsive element through phosphorylation of c-Rel and regulation of its transactivating activity. J Immunol 2006;176:4666–74.

21. Kim HH, Tharayil M, Rudd CE. Growth factor receptor-bound protein 2 SH2/SH3 domain binding to CD28 and its role in co-signaling. J BiolChem 1998;273:296–301.

22. D’Souza-Schorey C, Chavrier P. ARF proteins: roles in membrane traffic and beyond. Nat Rev Mol Cell Biol 2006;7:347–58.

23. Rudd CE, Schneider H. Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling. Nat Rev Immunol 2003;3:544–56.

24. Alessi DR, Deak M, Casamayor A, Caudwell FB, Morrice N, Norman DG, et al. 3-Phosphoinositide-dependent proteinkinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase. CurrBiol 1997;7: 776–89.

25. Frauwirth KA, Riley JL, Harris MH, Parry RV, Rathmell JC, Plas DR,, et al. The CD28 signaling pathway regulates glucose metabolism. Immunity 2002;16:769–777.

26. Schneider H, Valk E, Leung R, Rudd CE. CTLA-4 activation of phosphatidylinositol 3-kinase (PI 3-K) and protein kinase B (PKB ⁄ Akt) sustains T-cell anergy without cell death. PLoS ONE 2008;3(12):e3842.

27. Kirchhoff S, Muller WW, Li-Weber M, Krammer PH. Up-regulation of c-FLIPshort and reduction of activation-induced cell death in CD28-costimulated human T cells. Eur J Immunol 2000;30:2765–74.

28. Jones RG, Elford AR, Parsons MJ, Wu L, Krawczyk CM, Yeh WC, et al. CD28-dependent activation of protein kinase B ⁄ Akt blocks Fas-mediated apoptosis by preventing death-inducing signaling complex assembly. J Exp Med 2002;196:335–48.

29. Wood JE, Schneider H, Rudd CE. TcR and TcR-CD28 engagement of protein kinase B (PKB ⁄ AKT) and glycogen synthase kinase-3 (GSK-3) operates independently of guanine nucleotide exchange factor VAV-1. J BiolChem 2006;281:32385–94.

30. Kim H-H, Tharayil M, Rudd CE. Growth factor receptor-bound protein 2 SH2 /SH3 domain binding to CD28 and its role in cosignaling. J Biol Chem 1998;273:296–301.

31. Schneider H, Rudd C. CD28 and Grb2, relative to Gads or Grap, preferentially co-operate with Vav1 in the activation of NFAT ⁄ AP-1 transcription. Biochem Biophys Res Commun 2008;369:616–21.

32. Bustelo XR. Regulatory and signaling properties of the Vav family. Mol Cell Biol 2000; 20:1461–77.

33. Abbas A.K, Lichtman AH, Pillai S. Activation of T Lymphocytes. En: Abbas A.K, Lichtman AH, Pillai S. Celular and Molecular Immunology. 7th edition. Washington, DC: Elsevier Saunders;2011.203-24.

34. Hara H, Wada T, Bakal C, Kozieradzki I, Suzuki S, Suzuki N, et al. The MAGUK family protein CARD11 is essential for lymphocyte activation. Immunity 2003;18:763–75.

35. Wang D, Matsumoto R, You Y, Che T, Lin XY, Gaffen SL, et al. CD3 ⁄ CD28 costimulationinduced NF-kappaB activation is mediated by recruitment of protein kinase C-, Bcl10, and IkappaB kinase beta to the immunological synapse through CARMA1. Mol Cell Biol 2004;24:164–71.

36. Tanner MJ, Hanel W, Gaffen SL, Lin X. CARMA1 coiled-coil domain is involved in the oligomerization and subcellular localization of CARMA1 and is required for T cell receptor- induced NF-kappaB activation. J BiolChem 2007;282:17141–7.

37. Annibaldi A, Sajeva A, Muscolini M, Ciccosanti F, Corazzari M, Piacentini M, et al. CD28 ligation in the absence of TCR promotes RelA ⁄ NF-kappaB recruitment and trans-activation of the HIV-1 LTR. Eur J Immunol 2008;38: 1446–51.

38. Sathish JG, Johnson KG, LeRoy FG, Fuller KJ, Hallett MB, Brennan P, et al. Requirement for CD28 costimulation is lower in SHP-1-deficient T cells. Eur J Immunol 2001;31:3649–58.

39. Taylor A, Akdis M, Joss A, Akkoç T, Wenig R, Colonna M, et al. IL-10 inhibits CD28 and ICOS costimulations of T cells via src homology 2 domain-containing protein tyrosine phosphatase 1. J Allergy ClinImmunol 2007;120:76–83.

40. Boesteanu A, Katsikis P. Memory T cells need CD28 costimulation to remember. SeminImmunol. 2009; 21(2): 69–77.

41. Janakiram M, Abadi YM, Sparano JA, Zang X. T cell coinhibition and immunotherapy in human breast cancer. Discov Med. 2012;14(77):229-36.

42. Garbe C, Peris K, Hauschild A, Saiag P, Middleton M, Spatz A, et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2012. Eur J Cancer. 2012;48(15):2375-90.